Compare Global X Robotics and Artificial Intelligence ETF (BOTZ) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Robotics and Artificial Intelligence ETF vs BIO-TECHNE Corp — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.2, while BIO-TECHNE Corp trades at $71.23 (market cap $11.12B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, Global X Robotics and Artificial Intelligence ETF nearer its low. Which is the better fit depends on your goals.
| BOTZ | TECH | |
|---|---|---|
52-Week High | $41.63 | $71.38 |
52-Week Low | $31.99 | $43.31 |
Market Cap | — | $11.12B |
Sector | — | Health |
Enterprise Value | — | $11.20B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOTZ (Global X Robotics & Artificial Intelligence ETF) trades at $35.87, down 2.82% with a bearish technical signal. The ETF faces selling pressure as moving averages indicate a downtrend, though oversold RSI levels suggest potential near-term stabilization. Recent news highlights robotics and AI as emerging investment themes, with China's EV targets and humanoid robotics developments creating sector tailwinds.
The robotics/AI thematic ETF offers exposure to automation growth but lacks traditional valuation metrics. Key risks include sector concentration and technology disruption volatility. Analyst sentiment remains cautiously optimistic on long-term automation trends, though current technical weakness requires monitoring for entry points in this rapidly evolving sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Robotics and Artificial Intelligence ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
